• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

司帕沙星与现有抗微生物药物对呼吸道病原体的体外活性比较。

In-vitro activity of sparfloxacin in comparison with currently available antimicrobials against respiratory tract pathogens.

作者信息

Baquero F, Cantón R

机构信息

Department of Microbiology, Ramón y Cajal Hospital, National Institute of Health (INSALUD), Madrid, Spain.

出版信息

J Antimicrob Chemother. 1996 May;37 Suppl A:1-18. doi: 10.1093/jac/37.suppl_a.1.

DOI:10.1093/jac/37.suppl_a.1
PMID:8737121
Abstract

Bacterial resistance to antimicrobial agents is an ever-increasing problem. The in-vitro activity of sparfloxacin compared with that of currently available antimicrobial agents against pathogens implicated in respiratory tract infections is reviewed. Sparfloxacin is a fluoroquinolone active against both penicillin-susceptible and -resistant strains of Streptococcus pneumoniae. It is also active against many other respiratory tract pathogens and may be a suitable alternative for empirical therapy of community-acquired respiratory tract infections.

摘要

细菌对抗菌药物的耐药性是一个日益严重的问题。本文综述了司帕沙星与目前可用抗菌药物相比，对呼吸道感染相关病原体的体外活性。司帕沙星是一种氟喹诺酮类药物，对青霉素敏感和耐药的肺炎链球菌菌株均有活性。它对许多其他呼吸道病原体也有活性，可能是社区获得性呼吸道感染经验性治疗的合适替代药物。

相似文献

1
In-vitro activity of sparfloxacin in comparison with currently available antimicrobials against respiratory tract pathogens.司帕沙星与现有抗微生物药物对呼吸道病原体的体外活性比较。
J Antimicrob Chemother. 1996 May;37 Suppl A:1-18. doi: 10.1093/jac/37.suppl_a.1.
2
In vitro activity of sparfloxacin compared with ciprofloxacin and ofloxacin against respiratory tract pathogens.司帕沙星与环丙沙星及氧氟沙星相比对呼吸道病原体的体外活性。
Chemotherapy. 1993;39(1):32-5. doi: 10.1159/000238970.
3
In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against gram-positive and gram-negative pathogens from respiratory tract infections.环丙沙星、左氧氟沙星、洛美沙星、氧氟沙星、培氟沙星、司帕沙星和曲伐沙星对呼吸道感染革兰氏阳性和革兰氏阴性病原体的体外活性。
J Antimicrob Chemother. 1997 Sep;40(3):427-31. doi: 10.1093/jac/40.3.427.
4
Bacteriological activity of trovafloxacin, a new quinolone, against respiratory tract pathogens.新型喹诺酮类药物曲伐沙星对呼吸道病原体的细菌学活性。
Eur J Clin Microbiol Infect Dis. 1998 Jun;17(6):405-12. doi: 10.1007/BF01691573.
5
In vitro and in vivo antibacterial activities of Q-35, a novel fluoroquinolone.
Chemotherapy. 1995 Mar-Apr;41(2):100-12. doi: 10.1159/000239330.
6
[In vitro comparative activity (E test) of sparfloxacin and other 8 antimicrobial agents against bacteria isolated from patients with respiratory infections acquired in the community].
Rev Med Chil. 1995 Nov;123(11):1394-1401.
7
Microbiology of newer fluoroquinolones: focus on respiratory pathogens.新型氟喹诺酮类药物的微生物学：聚焦于呼吸道病原体。
Diagn Microbiol Infect Dis. 2002 Nov;44(3):213-20. doi: 10.1016/s0732-8893(02)00436-4.
8
In vitro activity of newer fluoroquinolones for respiratory tract infections and emerging patterns of antimicrobial resistance: data from the SENTRY antimicrobial surveillance program.新型氟喹诺酮类药物对呼吸道感染的体外活性及抗菌耐药性的新趋势：来自哨兵抗菌监测项目的数据
Clin Infect Dis. 2000 Aug;31 Suppl 2:S16-23. doi: 10.1086/314054.
9
Levofloxacin and sparfloxacin: new quinolone antibiotics.左氧氟沙星和司帕沙星：新型喹诺酮类抗生素。
Ann Pharmacother. 1998 Mar;32(3):320-36. doi: 10.1345/aph.17178.
10
In vitro activity of HSR-903, a new oral quinolone, against bacteria causing respiratory infections.新型口服喹诺酮类药物HSR-903对引起呼吸道感染的细菌的体外活性
Antimicrob Agents Chemother. 1999 Jul;43(7):1767-8. doi: 10.1128/AAC.43.7.1767.

引用本文的文献

1
Sparfloxacin in the treatment of purulent sinusitis-a multicentric study in Indian patients.司帕沙星治疗化脓性鼻窦炎——一项针对印度患者的多中心研究。
Indian J Otolaryngol Head Neck Surg. 1999 Jan;51(1):80-3. doi: 10.1007/BF02996857.
2
Sparfloxacin: An Overview of Its Efficacy in ENT Infections.司帕沙星：其在耳鼻喉感染中疗效的概述
Indian J Otolaryngol Head Neck Surg. 1997 Oct;49(4):415-21. doi: 10.1007/BF02994667.
3
Contribution of topoisomerase IV and DNA gyrase mutations in Streptococcus pneumoniae to resistance to novel fluoroquinolones.
肺炎链球菌中拓扑异构酶IV和DNA促旋酶突变对新型氟喹诺酮类药物耐药性的影响
Antimicrob Agents Chemother. 1999 Aug;43(8):2000-4. doi: 10.1128/AAC.43.8.2000.
4
Sparfloxacin resistance in clinical isolates of Streptococcus pneumoniae: involvement of multiple mutations in gyrA and parC genes.肺炎链球菌临床分离株对司帕沙星的耐药性：gyrA和parC基因中多个突变的作用
Antimicrob Agents Chemother. 1998 Sep;42(9):2193-6. doi: 10.1128/AAC.42.9.2193.
5
Comparative activities of clinafloxacin against gram-positive and -negative bacteria.克林沙星对革兰氏阳性菌和阴性菌的比较活性。
Antimicrob Agents Chemother. 1998 May;42(5):1269-73. doi: 10.1128/AAC.42.5.1269.
6
Effect of different combinations of sparfloxacin, oxacillin, and fosfomycin against methicillin-resistant staphylococci.
Eur J Clin Microbiol Infect Dis. 1997 Jul;16(7):535-7. doi: 10.1007/BF01708239.
7
Sparfloxacin. A review of its antibacterial activity, pharmacokinetic properties, clinical efficacy and tolerability in lower respiratory tract infections.司帕沙星。对其在下呼吸道感染中的抗菌活性、药代动力学特性、临床疗效及耐受性的综述。
Drugs. 1997 Apr;53(4):700-25. doi: 10.2165/00003495-199753040-00010.